It's worth noting that the veto message on the 2023 bill (which did not cap insulin prices, but only insurance copays for insulin) explicitly called out the Cal

It's worth noting that the veto message on the 2023 bill (which did not cap insulin prices, but only insurance copays for insulin) explicitly called out the CalRx project as providing the real solution, and noted that capping copays without addressing actual drug costs would result in the actual price just getting passed on to consumers via insurance premiums. It is also worth noting that this week Newsom signed SB 40 0f 2025, which did exactly the same thing in this area as the vetoed SB 90 of 2023, no doubt because the price side was also being adddressed simultaneously, with CalRx insulin to be on available in January when SB 40 goes into effect.